Sarepta Q3 revenue beats estimates

Overview

• Rare disease drugmaker's Q3 revenue fell 5% yr/yr but beat analyst expectations

• Non-GAAP operating income and EPS turned positive on lower R&D and disciplined expenses

• Company raised low end of FY revenue guidance and lowered high end of expense guidance

Outlook

• Company raises 2026 net product revenue guidance to $1.25 bln-$1.3 bln

• ELEVIDYS Q4 net product revenue expected to trend in line with Q3

Result Drivers

• ELEVIDYS LABEL CHANGE - Co said lower ELEVIDYS sales volume was due to updated label restricting use to ambulatory patients

• PMO FRANCHISE STRENGTH - Co cited strong PMO net product revenue as a driver for raising revenue guidance

• CONTRACT MANUFACTURING REVENUE - Higher contract manufacturing revenue from increased ELEVIDYS supply delivered to Roche partially offset lower product sales

Company press release:

Key Details

Reuters Recommended Reads

• Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

• Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

• Nov 4 - Revolution Medicines Q3 revenue reaches $198 mln after RASONQUE launch

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)